Clinical Trial Update: Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients [Phase 1]

View source ↗

Summary

Phase 1 study of NEUK203-13 in refractory neuroendocrine tumors and extensive-stage small cell lung cancer reports safety, tolerability and preliminary efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Small Cell Lung Cancer

Drugs mentioned

• NEUK203-13

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: SCLC, Extensive Stage, Neuroendocrine Tumors | Phase 1 | Status: NOT_YET_RECRUITING